Visualitza per autor "Iacoboni García-Calvo, Gloria Inés"
Ara mostrant els elements 1-4 d 4
-
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Hutchings, Martin; Morschhauser, Franck; Iacoboni García-Calvo, Gloria Inés; Carlo-Stella, Carmelo; Offner, Fritz C.; Sureda-Balari, Ana (American Society of Clinical Oncology, 2021-06-20) -
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
Jiménez Bernal, Isabel; Tazón Vega, Bárbara; Abrisqueta Costa, Pablo; Nieto Sáchica, Juan Camilo; Bobillo Varela, Sabela; Palacio García, Carlos; Carabia Juberó, Júlia; Munuera Codina, Magdalena; Puigdefabregas Horta, Lluis; Franco Jarava, Clara; Iacoboni García-Calvo, Gloria Inés; Crespo Maull, Marta; Bosch Albareda, Francesc (BMC, 2021-05-20) -
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Iacoboni García-Calvo, Gloria Inés; Villacampa Javierre, Guillermo; Martinez-Cibrian, Nuria; Bailén, Rebeca; Corral, Lucia Lopez; Sanchez, Jose M.; Abrisqueta Costa, Pablo; Barba Suñol, Pere (Wiley, 2021-05) -
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
Rejeski, Kai; Perez, Ariel; Iacoboni García-Calvo, Gloria Inés; Penack, Olaf; Bücklein, Veit; Jentzsch, Liv; Carpio Segura, Cecilia Carmen; Barba Suñol, Pere (BMJ, 2022-05)